A role for oleoylethanolamide in chronic lymphocytic leukemia

Leukemia

Volumn 28, Issue 7, 2014, Pages 1381-1387

  Masoodi, M ^a,b,c   Lee, E ^d   Eiden, M ^b,e   Bahlo, A ^d   Shi, Y ^d   Ceddia, R B ^f   Baccei, C ^g   Prasit, P ^g   Spaner, D E ^d,h,i  

^a NESTLÉ RESEARCH CENTER   (Switzerland)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d Canada   (Canada)

^e Metabolomx   (United States)

^f YORK UNIVERSITY   (Canada)

^g Current affiliation Inception Sciences Inc   (United States)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

adipocytes; bioactive lipids; chronic lymphocytic leukemia; lipidomics; nuclear receptors; PPARa

Indexed keywords

CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENZYME; FATTY ACID; FATTY ACID AMIDASE; N ACYLPHOSPHATIDYLETHANOLAMINE SPECIFIC PHOSPHOLIPASE D; N OLEOYLETHANOLAMINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADULT; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LIPOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADIPOCYTES; ADULT; AGED; AMIDOHYDROLASES; CASE-CONTROL STUDIES; CELL SURVIVAL; CELLS, CULTURED; FEMALE; HUMANS; HYDROLYSIS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; OLEIC ACID; OLEIC ACIDS;

EID: 84904046289     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.10     Document Type: Article

References (38)

1. Foà R, Guarini A. A mechanism-driven treatment for CLL? N Engl J Med 2013 369 85-87.
2. Cramer P, Hallek M. Prognostic factors in CLL-what do we need to know? Nat Rev Clin Oncol 2011 8 38-47.
3. Spaner DE, Lee E, Shi Y, Wen F, Li Y, Tung S et al. PPARalpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia 2013 27 1090-1099.
4. Masoodi M, Eiden M, Koulman A, Spaner D, Volmer DA. Comprehensive lipidomics analysis of bioactive lipids in complex regulatory networks. Anal Chem 2010 82 8176-8185.
5. Wong K, Brenneman F, Chesney A, Spaner D, Gorczynski R. Soluble CD200 is critical to engraft CLL cells in immunocompromised mice. Cancer Res 2012 72 4931-4943.
6. Hermanson DJ, Marnett LJ. Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev 2011 30 599-612.
7. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodr?́guez De Fonseca F et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003 425 90-93.
8. Hansen HS, Diep TA. N-acylethanolamines, anandamide and food intake. Biochem Pharmacol 2009 78 553-560.
9. Thabuis C, Tissot-Favre D, Bezelgues JB, Martin JC, Cruz-Hernandez C, Dionisi F et al. Biological functions and metabolism of OEA. Lipids 2008 43 887-894.
10. Oh dY, Lagakos W. The role of GPCRs in mediating the effect of fatty acids on inflammation and insulin sensitivity. Curr Opin Clin Nutr Metab Care 2011 14 322-327.
11. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A et al. Modulation of anxiety through AEA hydrolysis blockade. Nat Med 2003 9 76-81.
12. Tomic J, Lichty B, Spaner DE. Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood 2011 117 2668-2680.
13. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dö hner H et al. International workshop on CLL. Guidelines for the diagnosis and treatment of CLL. Blood 2008 111 5446-5456.
14. Tomic J, White D, Shi Y, Mena J, Hammond C, He L et al. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 2006 176 3830-3839.
15. Wolins NE, Quaynor BK, Skinner JR, Tzekov A, Park C, Choi K et al. OP9 mouse stromal cells rapidly differentiate into adipocytes characterization of a useful new model of adipogenesis. J Lipid Res 2006 47 450-460.
16. Tung S, Shi Y, Wong K, Zhu F, Gorczynski R, Laister R et al. PPARa and fatty acid oxidation mediate glucocorticoid resistance in CLL. Blood 2013 122 969-980.
17. Hammond C, Shi Y, Mena J, Tomic J, Cervi D, He L et al. Effect of serum and antioxidants on the immunogenicity of PKC-activated CLL cells. J Immunother 2005 28 28-39.
18. Gaidhu M, Fediuc S, Anthony N, So M, Mirpourian M, Perry R et al. Prolonged AICAR-induced AMPK activation promotes energy dissipation in white adipocytes novel mechanisms integrating HSL and ATGL. J Lipid Res 2009 50 704-715.
19. DiGirolamo M, Fine JB. Cellularity measurements. Methods Mol Biol 2001 155 65-75.
20. Li Y, Vecchiarelli L, Li Y, Egan S, Spaner D, Hough M et al. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood 2012 119 4486-4498.
21. Chen C, Bergsagel P, Paul H, Xu W, Lau A, Dave N et al. Single-agent lenalidomide in the treatment of previously untreated CLL. J Clin Oncol 2011 29 1175-1181.
22. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a PLD generating AEA and its congeners. J Biol Chem 2004 279 5298-5305.
23. Zhu C, Solorzano C, Sahar S, Realini N, Fung E, Sassone-Corsi P et al. Proinflammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol Pharmacol 2011 79 786-792.
24. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect CLL B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000 96 2655-2663.
25. Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. PPAR-alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol 2007 27 4238-4247.
26. Guzman M, Lo VJ, Fu J, Oveisi F, Blázquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferatoractivated receptor alpha (PPAR-alpha). J Biol Chem 2004 279 27849-27854.
27. Behan J, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS et al. Adipocytes impair leukemia treatment in mice. Cancer Res 2009 69 7867-7874.
28. Pond CM. Adipose tissue and the immune system. Prostaglandins Leukot Essent Fatty Acids 2005 73 17-30.
29. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 2010 16 880-886.
30. Shi H, Kokoeva M, Inouye K, Tzameli I, Yin H, Flier J. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006 116 3015-3025.
31. Holzer R, Park E, Li N, Tran H, Chen M, Choi C et al. Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. Cell 2011 147 173-184.
32. Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2 a meta-analysis of observational studies. Blood 2012 119 4845-4850.
33. Capurso C, Capurso A. From excess adiposity to insulin resistance the role of free fatty acids. Vascul Pharmacol 2012 57 91-97.
34. Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005 54 1640-1648.
35. Yoon J, Lafarge S, Dawe D, Lakhi S, Kumar R, Morales C et al. Association of IL6 and IL8 with poor prognosis in elderly patients with CLL. Leuk Lymphoma 2012 53 1735-1742.
36. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia mediators, signaling, and metabolic pathways. Cell Metab 2012 16 153-166.
37. Das S, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B et al. Adipose triglyceride lipase contributes to cancer associated cachexia. Science 2011 333 233-238.
38. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010 140 49-61.